Glaucoma is the most common cause of irreversible vision loss in the world. The only proven method to treat the disease by reduction of intraocular pressure (IOP). IOP act as a modifiable risk factor in glaucoma. Liposomes have been considered as one of the effective pharmaceutical therapies in reducing IOP in glaucoma and receive widespread attention in research due to their special characteristics. Recent studies such as liposomal Latanoprost are still in failure clinical trials. This review focus on the therapeutic application of liposomal in the neuro-ocular brain. The routes of drug administration for the treatment of glaucoma are topical, systemic, periocular and intravitreal. The treatment of glaucoma using drug-carrier liposome shows less invasive and more effective when applied topically since it contains bilayer vesicles which can breach the corneal barrier. To conclude, using the nanocarrier for the topical administration technique is better compared to normal drug application as it is more effective and less invasive.